Precision Oncology and Targeted Therapy in Shanghai: 2026 Guide

China's Genomic Medicine Ecosystem

China has one of the world's most rapidly advancing precision oncology ecosystems. Domestic NGS companies (Burning Rock/燃石, Geneseeq/世和, Anchor/安捷) offer comprehensive genomic profiling at a fraction of Western costs, and Chinese-developed targeted drugs and PD-1 inhibitors are often significantly more affordable.

Biomarker-Driven Treatment

NSCLC: EGFR (osimertinib, aumolertinib/阿美替尼, furmonertinib/伏美替尼 — Chinese 3rd-gen), ALK (alectinib, ensartinib), ROS1 (entrectinib, crizotinib), KRAS G12C (sotorasib, adagrasib), MET exon 14 (savolitinib).

Breast: HER2 (trastuzumab, pertuzumab, T-DXd, pirtobrutinib; Chinese-developed RC48-ADC/维迪西妥单抗), BRCA (olaparib).

Ovarian: BRCA/HRD (olaparib, niraparib, pamiparib/帕米帕利 Chinese).

Colorectal: RAS/BRAF status determines anti-EGFR; HER2 amplification (trastuzumab + pertuzumab); MSI-H (pembrolizumab).

Melanoma: BRAF V600E (dabrafenib + trametinib).

Chinese Immuno-Oncology Drugs

Chinese-developed PD-1 inhibitors are widely used in Shanghai:

Camrelizumab (卡瑞利珠/艾瑞卡)

Sintilimab (信迪利/达伯舒)

Tislelizumab (替雷利珠/百泽安)

Toripalimab (特瑞普利/拓益)

These are often 30-60% cheaper than pembrolizumab/nivolumab after Chinese national insurance coverage, with comparable outcomes across most indications.

NGS Testing in Shanghai

Tissue or liquid biopsy (blood ctDNA)

500-800 gene panels available, typically ¥8,000–20,000

Results in 7-14 days

Burning Rock and Geneseeq both have international reports in English

Cost Reference

NGS panel: ¥8,000–20,000. Chinese PD-1: ¥3,000–8,000/cycle after insurance (vs pembrolizumab ~¥17,000). 3rd-gen EGFR TKI: ¥5,000–15,000/month. ADC drugs (T-DXd, RC48): ¥20,000–40,000/cycle.